About 90% of pancreatic cancer cases include a mutation called KRAS, meaning nonpersonalized vaccines, which could be ...

The University of Texas MD Anderson Cancer Center is conducting parallel research on a universal vaccine against pancreatic ...

state of greater than 90% of all KRAS mutations and to provide complete target coverage in tumors. These properties have the potential to translate into best-in-class safety and efficacy.

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

The grant to Dr. Shah provides for the issuance of 191,624 stock options. Additionally, the grants to the two employees provide for the issuance of an aggregate of 21,000 stock options. Each grant ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

A new analysis of data from the KeyNote-042 trial in previously-untreated NSCLC has shown that the drug is effective regardless of whether a patient’s tumour bears KRAS mutations – which make ...

durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens and a strong correlation between DFS and T cell response.

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of ...